Michael Albin

Genturi, Inc. operates as an early stage genomics technology company. It develops long DNA molecule analysis technology for research and subsequent clinical applications. The company was founded by J. Michael Ramsey and Laurent Menard in 2015 and is headquartered in Woburn, MA.

MOBILion Systems, Inc. offers paradigm-shifting platform technology. It will Develop a cost effective analytical system with a small footprint, high throughput, ultra-high sensitivity and selectivity enabling use in commercial applications unattainable by conventional ion mobility separation devices. The company was founded in 2015 and is headquartered in , Chadds Ford, PA.

Aquyre Biosciences, Inc. is a biotech company that created Celtivity™, a rapid digital specimen adequacy assessment tool that can identify the presence of cancer cells and immune cells in a biopsy in just two minutes. The company is based in Weston, MA and was founded by Bertrand Le Conte de Poly, Claude Boccara. The assessment is presented as a cellular heatmap, making analysis and detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. Floyd Samuel Eberts has been the CEO of the company since 2023.

Applera Corp. manufactures medical instruments

Applied Biosystems, Inc. is a company that provides integrated systems for sequencing, flow cytometry, and various types of PCR. The company is based in Foster City, CA. The company's products cover the entire process from sample preparation to data analysis. The company was founded by Chris Yoo, Marvin H. Caruthers, Michael W. Hunkapiller, and Leroy E. Hood. Applied Biosystems was acquired by Invitrogen Corp. from Applera Corp. on November 21, 2008 for $6,417.85 million.

Decipher Biosciences, Inc. is a commercial-stage precision oncology company which engages in patient care improvement. The Company?s differentiated approach measures the biological activity of a patient?s entire tumor genome, known as whole transcriptome analysis, and applies proprietary machine learning algorithms to improve therapy selection and accelerate adoption of new therapies into the standard of care. Its novel prostate cancer genomic testing products examine the underlying biology of a patient?s tumor, enabling physicians to select an optimal therapy. The firm?s whole transcriptome analysis of clinical patient samples from its commercial channel and its participation in practice-changing clinical trials has allowed it to build and expand its Decipher GRID database GRID. The company was founded by Elai Davicioni, Timothy J. Triche, Bruce A. Schmidt, and Jonathan D. Buckley and is headquartered in San Diego, CA.